Dimemorfan

Side effects

Adverse effects include nausea, somnolence, dry mouth, and decreased appetite.

Pharmacology

Dimemorfan is an analogue of dextromethorphan (DXM) and its active metabolite dextrorphan (DXO), and similarly to them, acts as a potent agonist of the σ1 receptor (Ki = 151 nM). However, unlike DXM and DXO, it does not act significantly as an NMDA receptor antagonist (Ki = 16,978 nM), and for this reason, lacks dissociative effects, thereby having reduced side effects and abuse potential in comparison. Similarly to DXM and DXO, dimemorfan has only relatively low affinity for the σ2 receptor (Ki = 4,421 nM).

References

References

1. (14 November 2014). "The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies". Springer.
2. (15 January 2015). "Textbook of Palliative Medicine and Supportive Care, Second Edition". CRC Press.
3. (1997). "The nonnarcotic antitussive drug dimemorfan: a review". Clinical Therapeutics.
4. (1 January 2005). "Lexi-Comp's Drug Information Handbook International: With Canadian and International Drug Monographs". Lexi-Comp.
5. (1991). "Drugs Available Abroad, 1st Edition". Derwent Publications Ltd..
6. (November 2009). "The pharmacology of sigma-1 receptors". Pharmacology & Therapeutics.
7. (20 April 2012). "Therapeutic Targets: Modulation, Inhibition, and Activation". John Wiley & Sons.
8. (March 1999). "Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan". Brain Research.
9. (April 2005). "The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan". British Journal of Pharmacology.